Sesame Alternatives: How the Marketplace Model Compares

This article is part of the PlexusDx Education Hub — practical, evidence-based guidance on GLP-1 therapies, weight management, and the genetic factors behind every metabolic decision. Browse all Peptides & GLP-1 education

Independent editorial review. PlexusDx holds no commercial relationship with Sesame or its parent company, and this page carries no affiliate links or sponsored placement.

People who search for a Sesame alternative are usually already comfortable with telehealth — they simply want to know what else the GLP-1 category offers and where a marketplace like Sesame sits among the choices. This review maps that landscape as of April 2026, then points to the one variable almost no telehealth checkout captures. It is orientation, not a buying recommendation.

Where Sesame sits in the telehealth landscape

Sesame (Sesame Care) runs on a marketplace model: rather than operating one in-house clinic, it connects patients with independent licensed providers who can evaluate them and, where appropriate, write a GLP-1 prescription. That prescription is then filled through either a retail pharmacy for FDA-approved brand products or a 503A compounding pharmacy for compounded semaglutide or tirzepatide. For current program details and pricing, consult Sesame’s official website.

The marketplace model, in plain terms

Compared with a vertically integrated program, a marketplace routes you to whichever participating clinician has availability. The core steps are consistent across the category: you complete an intake covering weight, medical history, and current medications; a licensed clinician reviews it and issues a prescription if you qualify; the order is fulfilled by a retail or compounding pharmacy; and follow-up visits support dose titration. What differs is provider continuity, the pharmacy partner, and how the subscription is billed.

Comparing the fulfillment routes: retail versus compounded

The most consequential difference between GLP-1 alternatives is the dispensing pathway. A retail route supplies branded, FDA-approved products; a 503A compounding route supplies a compounded semaglutide or tirzepatide preparation. Neither is inherently superior — they operate under different regulatory frameworks, cost structures, and availability. When you set Sesame beside another service, the pharmacy pathway is often the real distinction hiding behind similar-looking marketing.

What the GLP-1 evidence base actually says

Every legitimate program in this space rests on the same pharmacology: GLP-1 receptor agonists such as semaglutide, liraglutide, and dulaglutide, and the GIP/GLP-1 dual agonist tirzepatide. The anchoring trials are the STEP program (semaglutide for weight management, The New England Journal of Medicine, 2021), SURMOUNT (tirzepatide for weight management, NEJM 2022), and SURMOUNT-OSA (tirzepatide for obstructive sleep apnea, NEJM 2024). Populations and endpoints differ between them, so results read most honestly trial by trial rather than as a single headline.

The alternative most programs skip: your genetic baseline

Whichever service you choose, none of them examines the genetic architecture underneath your metabolism. Variants in FTO (the fat-mass and obesity-associated gene), GLP1R (the receptor every GLP-1 compound targets), MC4R (central to satiety and energy balance), and TCF7L2 (tied to glucose handling and GLP-1 secretion) describe the terrain a clinician is prescribing into. These are pathway-level markers — they do not predict how you will respond to any specific medication, but they add context a telehealth intake form never asks for.

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — available as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. The differentiator is the upstream genetic context: before starting any GLP-1 pathway protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights — including FTO, MC4R, and TCF7L2 variants that shape your baseline GLP-1, appetite-regulation, and energy-balance biology. That is the test before you invest approach, turning guesswork into an informed conversation with your provider.

Not affiliated: PlexusDx is not affiliated with Sesame and has no commercial relationship with the companies reviewed in this article.

Related reading on PlexusDx: GLP 1 Drugs, GLP 1 Hormone, What Is GLP 1, GLP 1 What Is.

Disclaimer: This article is educational. PlexusDx is not affiliated with Sesame and has no commercial relationship with the companies reviewed. PlexusDx offers semaglutide and tirzepatide through its own Weight Management Protocols — this review compares approaches in the GLP-1 telehealth space. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways — it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Weighing your options? See the PlexusDx Weight Management Protocols for semaglutide and tirzepatide with genetic context, or start with the Precision Peptide Genetic Test to understand your pathway first.

Frequently Asked Questions

What should I compare when weighing Sesame against alternatives?

Look past the marketing to four things: whether a licensed clinician evaluates you before prescribing, whether the pharmacy partner is retail or a 503A compounder, how the subscription is billed, and whether follow-up is included. Those four factors separate most GLP-1 alternatives far more than surface branding does.

Is a compounded alternative the same as a branded GLP-1?

Not exactly. Compounded semaglutide or tirzepatide is prepared by a 503A compounding pharmacy and follows a different regulatory framework than an FDA-approved branded product from a retail pharmacy. Both may be legitimate routes, but they differ in oversight, cost, and availability. Confirm the pathway before committing to any service.

Does the Precision Peptide Genetic Test tell me which program to pick?

No. The test does not predict response to Sesame, any competitor, or any specific compound. It maps pathway-level variants in FTO and MC4R, and TCF7L2 that describe your baseline metabolic biology — context that applies no matter which telehealth service ultimately writes the prescription for you.

How is the PlexusDx approach different from a marketplace?

PlexusDx pairs semaglutide and tirzepatide protocols with upstream genetic insight rather than routing you to whichever clinician is free. The emphasis is understanding your GLP-1, appetite, and energy-balance genetics first, so the protocol conversation with your provider starts from data rather than a generic intake form.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education